Discontinuation of imatinib may be possible in chronic myelogenous leukemia


  • Mary Kay Barton MD

  • Note: The name of this section has been changed from “News & Views” to “Perspectives: Research in Context.” It continues to provide the context for major developments in cancer prevention, detection, and treatment.

No abstract is available for this article.